Sort
51,593 grants matching “hepatitis”
National HIV Behavioral Surveillance System
$614,418Kathleen A Brady · Philadelphia Departmentof Public Health · U1B · FY2015 · PS
Pre-clinical Validation of A Novel Protein Drug Candidate for ASH and NASH Treatment
$614,398Jenny J Yang · Georgia State University · R01 · FY2022 · DK
Pre-clinical Validation of A Novel Protein Drug Candidate for ASH and NASH Treatment
$614,398Jenny J Yang · Georgia State University · R01 · FY2023 · DK
Pre-clinical Validation of A Novel Protein Drug Candidate for ASH and NASH Treatment
$614,398Zhi-Ren Liu · Georgia State University · R01 · FY2021 · DK
Geography, networks, and risk in disease transmission
$614,342Richard B Rothenberg · Georgia State University · R01 · FY2009 · DA
Core 1: Administrative Core
$614,325Bruce R Schackman · Weill Medical Coll Of Cornell Univ · P30 · FY2023 · DA
Mitochondrial DAMPs-driven Mechanisms of Liver Fibrosis in NASH
$614,322Yury Popov · Beth Israel Deaconess Medical Center · R01 · FY2025 · DK
Interventions to Increase HBV Vaccination in STD Clinics
$614,315Indiana Univ-Purdue Univ At Indianapolis · R01 · FY2003 · AI
Exposome and Precision Medicine in NAFLD
$614,249Matthew C Cave · University Of Louisville · R01 · FY2021 · ES
The characterization of Cela2a, a novel disease gene for metabolic syndrome in health and diseases
$614,168Arya Mani · Yale University · R01 · FY2025 · DK
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS
$614,163Margie Clapper · Research Inst Of Fox Chase Can Ctr · N01 · FY2022 · CA
Mechanisms of Insulin Resistance in Man
$614,135Rita Basu · Mayo Clinic Rochester · R01 · FY2015 · DK
Mechanisms of Insulin Resistance in Man
$614,135Rita Basu · Mayo Clinic Rochester · R01 · FY2016 · DK
In Vivo And In Vitro Studies Of Hepatitis E Virus
$614,121Suzanne U Emerson · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Transforming Clinical and Translational Research and Education at Rockefeller
$613,980Barry Coller · Rockefeller University · KL2 · FY2007 · RR
Immune Escape Strategies in HCV infection
$613,947Hugo R Rosen · University Of Colorado Denver · U19 · FY2007 · AI
Novel pathways in the pathogenesis and pathophysiology of NAFLD in Hispanics
$613,874Sonia Michael Najjar · Ohio University Athens · R01 · FY2019 · MD
Reverse-engineering precision liver cancer chemoprevention
$613,866Yujin Hoshida · Ut Southwestern Medical Center · R01 · FY2023 · CA
Altered Hepatic Disposition of Anionic Drugs-Mechanisms
$613,833Kim L Brouwer · Univ Of North Carolina Chapel Hill · R01 · FY2014 · GM
Iron Status: A Pathway Analysis in Multiple Ethnicities
$613,819Christine E McLaren · University Of California-Irvine · R01 · FY2009 · HL
Mindful Body Awareness Training as an Adjunct to Medication Assisted Treatment for Opioid Use Disorder
$613,713Cynthia J Price · University Of Washington · R33 · FY2021 · AT
HIV, HCV and STI Risk Associated with Nonmedical Use of Prescription Opioids
$613,713Pedro Mateu-Gelabert · National Development And Research Institutes, Inc. · R01 · FY2014 · DA
Statin Therapy for patients with compensated Cirrhosis
$613,662Elliot Tapper · University Of Michigan At Ann Arbor · U01 · FY2025 · DK
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression
$613,493Phyllis C Tien · Northern California Institute/Res/Edu · R01 · FY2016 · DK
Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma
$613,402Yazhen Zhu · University Of California Los Angeles · R01 · FY2024 · CA